[{"address1": "Gooimeer 2-35", "city": "Naarden", "zip": "1411 DC", "country": "Netherlands", "phone": "31 35 206 2971", "website": "https://www.newamsterdampharma.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.", "fullTimeEmployees": 68, "companyOfficers": [{"maxAge": 1, "name": "Dr. Michael Harvey Davidson FACC, Facp., M.D.", "age": 68, "title": "CEO, President, Executive Board Member & Director", "yearBorn": 1956, "fiscalYear": 2024, "totalPay": 1122237, "exercisedValue": 0, "unexercisedValue": 51427864}, {"maxAge": 1, "name": "Dr. Johannes Jacob Pieter Kastelein FESC, M.D., Ph.D.", "age": 70, "title": "Founder, Chief Scientific Officer, Member of Executive Board & Director", "yearBorn": 1954, "fiscalYear": 2024, "totalPay": 813077, "exercisedValue": 4094829, "unexercisedValue": 35092304}, {"maxAge": 1, "name": "Mr. Mayur Amrat Somaiya", "age": 50, "title": "Chief Financial Officer", "yearBorn": 1974, "fiscalYear": 2024, "totalPay": 841238, "exercisedValue": 0, "unexercisedValue": 3954412}, {"maxAge": 1, "name": "Mr. Douglas F. Kling", "age": 51, "title": "Chief Operating Officer", "yearBorn": 1973, "fiscalYear": 2024, "totalPay": 913742, "exercisedValue": 0, "unexercisedValue": 17441960}, {"maxAge": 1, "name": "Ms. Juliette  Audet M.B.A., M.Sc.", "age": 37, "title": "Chief Strategy & Business Officer", "yearBorn": 1987, "fiscalYear": 2024, "totalPay": 653039, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Louise  Kooij", "age": 48, "title": "Chief Accounting Officer", "yearBorn": 1976, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Matthew  Philippe", "title": "Executive VP &Head of Investor Relations", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Bob  Rambo", "title": "Executive Vice President of Marketing", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Maryellen  McQuade", "title": "Chief People Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Marc  Ditmarsch M.D.", "age": 57, "title": "Chief Development Officer", "yearBorn": 1967, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 13.6, "open": 13.85, "dayLow": 13.8, "dayHigh": 13.85, "regularMarketPreviousClose": 13.6, "regularMarketOpen": 13.85, "regularMarketDayLow": 13.8, "regularMarketDayHigh": 13.85, "beta": -0.013, "volume": 1203, "regularMarketVolume": 1203, "averageVolume": 4372, "averageVolume10days": 3410, "averageDailyVolume10Day": 3410, "bid": 13.51, "ask": 0.0, "bidSize": 1, "askSize": 0, "fiftyTwoWeekLow": 5.45, "fiftyTwoWeekHigh": 16.75, "fiftyDayAverage": 10.53182, "twoHundredDayAverage": 10.42959, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "profitMargins": -2.58905, "floatShares": 55613680, "bookValue": 6.919, "priceToBook": 1.9945079, "netIncomeToCommon": -165715008, "52WeekChange": 0.80628276, "SandP52WeekChange": 0.15005577, "quoteType": "EQUITY", "currentPrice": 13.8, "recommendationKey": "none", "totalCash": 739161984, "totalCashPerShare": 6.563, "ebitda": -172616000, "totalDebt": 328000, "quickRatio": 20.785, "currentRatio": 21.085, "totalRevenue": 64006000, "debtToEquity": 0.042, "revenuePerShare": 0.597, "returnOnAssets": -0.17118, "returnOnEquity": -0.28426, "grossProfits": 64006000, "freeCashflow": -85028000, "operatingCashflow": -124122000, "revenueGrowth": 7.401, "grossMargins": 1.0, "ebitdaMargins": -2.69687, "operatingMargins": -1.86132, "financialCurrency": "USD", "symbol": "NAMSW", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": true, "customPriceAlertConfidence": "HIGH", "shortName": "NewAmsterdam Pharma Company N.V", "longName": "NewAmsterdam Pharma Company N.V.", "regularMarketChangePercent": 1.4705868, "regularMarketPrice": 13.8, "corporateActions": [], "regularMarketTime": 1755288000, "exchange": "NGM", "messageBoardId": "finmb_685404834", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "marketState": "CLOSED", "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1612967400000, "regularMarketChange": 0.19999981, "regularMarketDayRange": "13.8 - 13.85", "fullExchangeName": "NasdaqGM", "averageDailyVolume3Month": 4372, "fiftyTwoWeekLowChange": 8.35, "fiftyTwoWeekLowChangePercent": 1.5321102, "fiftyTwoWeekRange": "5.45 - 16.75", "fiftyTwoWeekHighChange": -2.9499998, "fiftyTwoWeekHighChangePercent": -0.17611939, "fiftyTwoWeekChangePercent": 80.62827, "fiftyDayAverageChange": 3.26818, "fiftyDayAverageChangePercent": 0.3103148, "twoHundredDayAverageChange": 3.37041, "twoHundredDayAverageChangePercent": 0.3231584, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2022-11-23", "prevName": "Frazier Lifesciences Acquisition Corporation", "nameChangeDate": "2025-08-15", "cryptoTradeable": false, "displayName": "NewAmsterdam Pharma Company", "trailingPegRatio": null, "__fetch_time": "2025-08-16"}]